Table 1

Anti-Tim-3 clinical trials

Reagent name (manufacturer) identifierPhaseCoblockadeCancer typeFurther reading
MGB453 (Novartis Pharmaceuticals)IgG4 (S228P)NCT02608268I/IIbAnti-PD-1Advanced malignancies 99 100
MGB453 (Novartis Pharmaceuticals)IgG4 (S228P)NCT03066648IMonotherapy or anti-PD-1 or Hypomethylating Agent (HMA)(decitabine or azacitidine)AML, MDS 14 99 100
MGB453 (Novartis Pharmaceuticals)IgG4 (S228P)NCT03946670IIRandomized; HMA (decitabine or azacitidine)MDS 14 99 100
TSR-022 (Tesaro)IgG4NCT02817633IAnti-PD-1Advanced solid tumors 101–104
TSR-022 (Tesaro)IgG4NCT030680508IIAnti-PD-1Liver cancer 101–103
Sym023 (Symphogen A/S)?NCT03489343IMonotherapySolid tumors and lymphomas 105
Sym023 (Symphogen A/S)?NCT03311412IAnti-PD-1Solid tumors and lymphomas 105
BGBA425 (BeiGene)IgG1 (variant, engineered to remove FcγR binding)NCT03744468IAnti-PD-1Solid tumors 106
R07121661 (Hoffmann-La Roche)Bispecific antibodyNCT03708328 (development halted)ITargets both TIM-3 and PD-1Solid tumors metastatic melanoma, NSCLC 107
LY3321367 (Eli Lilly and Company)?NCT03099109 (development halted)Ia/IbAnti-PD-L1Advanced relapsed/refractory solid tumors 108
ICAGN02390 (Incyte Corporation)IgG1k, N297A (Fc-engineered silent)NCT03652077IMonotherapySolid tumors 109
BMS-986258 (Bristol-Myers Squibb)IgG1, silentNCT03446040IAnti-PD-1, human recombinant hyaluronidaseAdvanced cancerN/A
  • AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; N/A, not applicable; NSCLC, non-small cell lung cancer; TIM-3, T-cell immunoglobulin and mucin domain 3.